Amneal Pharmaceuticals, Inc. Contracts & Agreements

Description of Registrants Securities (Filed With SEC on March 14, 2024)

Term Sheet, dated as of October 16, 2023 among, the Company, Amneal Pharmaceuticals LLC and the Amneal Group Representative (Filed With SEC on October 17, 2023)

Amendment No.1 to Revolving Credit and Term Loan Agreement, dated as of April 20, 2023, by and among Rondo Holdings, LLC, Rondo Intermediate Holdings, LLC, the Subsidiary Loan... (Filed With SEC on August 8, 2023)

Amendment No. 1 to Term Loan Credit Agreement, dated as of May 30, 2023, entered into by and among Amneal Pharmaceuticals LLC, the Guarantors, and JPMorgan Chase Bank, N.A. as... (Filed With SEC on August 8, 2023)

Amneal Pharmaceuticals, Inc. 2018 Incentive Award Plan, as amended and restated (Filed With SEC on August 8, 2023)

Modification No. 2 to Employment Agreement, dated February 21, 2023, by and among Amneal Pharmaceuticals, Inc. and Anastasios Konidaris (Filed With SEC on May 9, 2023)

Modification No. 1 to Employment Agreement, dated February 21, 2023, by and among Amneal Pharmaceuticals, Inc. and Nikita Shah (Filed With SEC on May 9, 2023)

Modification No. 2 to Employment Agreement, dated February 21, 2023, by and among Amneal Pharmaceuticals, Inc. and Andrew Boyer (Filed With SEC on May 9, 2023)

Employment Agreement dated September 1, 2022, by and between Amneal Pharmaceuticals, Inc. and Gustavo Pesquin (Filed With SEC on September 6, 2022)

Amneal Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended on August 4, 2022 (Filed With SEC on August 8, 2022)

ABL Guarantee and Collateral Agreement, dated as of June 2, 2022, by and among the loan parties from time-to-time party thereto and Truist Bank, as administrative agent and... (Filed With SEC on June 2, 2022)

Revolving Credit Agreement, dated as of June 2, 2022, by and among Amneal Pharmaceuticals LLC, as the borrower, Truist Bank, as administrative agent and collateral agent and the... (Filed With SEC on June 2, 2022)

Share Purchase Agreement, dated November 2, 2021, by and among Puniska Healthcare Pvt. Ltd. and Amneal Pharmaceuticals Private Limited (Filed With SEC on March 1, 2022)

Asset Purchase Agreement, dated December 30, 2021, by and among Amneal and Saol Therapeutics (Filed With SEC on January 5, 2022)

Amneal Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended and restated on May 5, 2021 (Filed With SEC on August 9, 2021)

Employment Agreement by and among Amneal Pharmaceuticals, Inc. and Nikita Shah, dated as of July 29, 2020 (Filed With SEC on May 7, 2021)

Employment Agreement by and among Amneal Pharmaceuticals, Inc. and Joseph Todisco, dated as of July 29, 2020 (Filed With SEC on May 7, 2021)

Amneal Pharmaceuticals, Inc. Non- Employee Director Compensation Policy (Filed With SEC on March 1, 2021)

Form of Amneal Pharmaceuticals, Inc. 2018 Incentive Award Plan Performance Restricted Stock Unit Grant Notice and Performance Restricted Stock Unit Agreement (2020) (Filed With SEC on March 1, 2021)

Membership Interest Purchase Agreement, dated January 11, 2021, by and among Kashiv BioSciences, LLC and Amneal Pharmaceuticals LLC (Filed With SEC on January 12, 2021)

Modification No. 1 to Employment Agreement, effective as of August 1, 2020, by and among Amneal Pharmaceuticals LLC, Amneal Holdings, LLC and Andrew Boyer (Filed With SEC on November 6, 2020)

Amneal Pharmaceuticals LLC Severance Plan and Summary Plan Description (Filed With SEC on August 6, 2020)

Form of Amneal Pharmaceuticals, Inc. 2018 Incentive Plan Performance Restricted Stock Unit Grant Notice and Performance Restricted Stock Unit Agreement (Filed With SEC on May 11, 2020)

First Amendment to Separation Agreement between David Buchen, Amneal Pharmaceuticals, Inc. and Amneal Pharmaceuticals LLC, dated as of November 4, 2019 (Filed With SEC on May 11, 2020)

Separation Agreement between David Buchen, Amneal Pharmaceuticals, Inc. and Amneal Pharmaceuticals LLC, dated as of August 2, 2019 (Filed With SEC on May 11, 2020)

Employment Agreement by and among Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals, Inc. and David Buchen, dated as of December 28, 2018 (Filed With SEC on May 11, 2020)

Separation Agreement between Todd Branning, Amneal Pharmaceuticals, Inc. and Amneal Pharmaceuticals LLC, dated as of March 11, 2020 (Filed With SEC on May 11, 2020)

Employment Agreement, dated March 11, 2020, by and among Amneal Pharmaceuticals LLC, the Company and Anastasios (Tasos) G. Konidaris (Filed With SEC on March 12, 2020)

Amneal Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (Filed With SEC on March 2, 2020)

Description of Registrants Securities (Filed With SEC on March 2, 2020)

Revolving Credit and Term Loan Agreement, dated as of January 31, 2020, by and among Rondo Intermediate Holdings and LLC and Rondo Holdings, LLC, the lenders from time to time... (Filed With SEC on February 4, 2020)

Guaranty and Security Agreement, dated as of January 31, 2020, by and among Rondo Intermediate Holdings, LLC, and Rondo Holdings, LLC, AvKARE, R&S Northeast, and the... (Filed With SEC on February 4, 2020)

Amended and Restated Operating Agreement of Rondo Partners, LLC (Filed With SEC on February 4, 2020)

Equity Purchase Agreement, dated December 10, 2019, by and among the Jerry Brian Shirley Business Trust, the Darren Thomas Shirley Business Trust, the Steve Shirley Business... (Filed With SEC on December 10, 2019)

Amendment No. 1, dated as of August 2, 2019, to Second Amended and Restated Stockholders Agreement, by and among Amneal Pharmaceuticals Holding Company, LLC, a Delaware limited... (Filed With SEC on August 5, 2019)

Form of Tripartite Letter Agreement Credit Suisse (Filed With SEC on August 5, 2019)

Form of Tripartite Acknowledgment and Agreement Morgan Stanley (Filed With SEC on August 5, 2019)

Separation Agreement between Robert Stewart, Amneal Pharmaceuticals, Inc. and Amneal Pharmaceuticals LLC, dated as of August 2, 2019 (Filed With SEC on August 5, 2019)

Amneal Pharmaceuticals LLC 2019 Severance Plan (Filed With SEC on May 9, 2019)

Separation Agreement, dated February 5, 2019, by and between Sheldon Hirt and Amneal Pharmaceuticals, Inc (Filed With SEC on March 1, 2019)

Form of Amneal Pharmaceuticals, Inc. 2018 Incentive Award Plan Performance Restricted Stock Unit Grant Notice and Performance Restricted Stock Unit Agreement (Filed With SEC on March 1, 2019)

Separation Agreement, dated February 28, 2019, by and between Bryan Reasons and Amneal Pharmaceuticals, Inc (Filed With SEC on March 1, 2019)

Amendment No. 1 to Third Amended and Restated Limited Liability Company Agreement of Amneal Pharmaceuticals LLC, dated as of February 14, 2019, with effect as of May 4, 2018 (Filed With SEC on March 1, 2019)

Employment Agreement, dated January 21, 2019, by and among the Company, Amneal Pharmaceuticals LLC, and Todd P. Branning (Filed With SEC on January 24, 2019)

Amneal Pharmaceuticals, Inc. 2018 Incentive Award Plan (Filed With SEC on August 9, 2018)

Amendment No. 2, dated as of December 16, 2017, to the Business Combination Agreement, dated as of October 17, 2017, by and among Impax Laboratories, Inc., Atlas Holdings, Inc.,... (Filed With SEC on May 7, 2018)

Purchase and Sale Agreement, dated as of May 7, 2018, by and among Amneal Phrmaceuticals LLC, Gemini Laboratories, LLC, the parties signatory thereto and the Sellers Representative (Filed With SEC on May 7, 2018)

Second Supplemental Indenture (Filed With SEC on May 7, 2018)

Business Combination Agreement, dated as of October 17, 2017, among Impax Laboratories, Inc., Amneal Pharmaceuticals LLC, Atlas Holdings, Inc. and K2 Merger Sub Corporation (Filed With SEC on May 7, 2018)

Amendment No. 1, dated as of November 21, 2017, to the Business Combination Agreement, dated as of October 17, 2017, by and among Impax Laboratories, Inc., Atlas Holdings, Inc.,... (Filed With SEC on May 7, 2018)

PIPE Side Letter, dated November 21, 2017, by and among Amneal Holdings, LLC, Atlas Holdings, Inc., and TPG Improv Holdings, L.P (Filed With SEC on May 7, 2018)

Indenture, dated as of June 30, 2015, between Impax Laboratories, Inc. and Wilmington Trust, National Association, as trustee (Filed With SEC on May 7, 2018)

Supplemental Indenture, dated as of November 6, 2017, between the Company and Wilmington Trust, National Association, as trustee (Filed With SEC on May 7, 2018)

Second Supplemental Indenture, dated as of May 4, 2018, between the Company and WilmingtonvTrust, National Association, as trustee (Filed With SEC on May 7, 2018)

Commitment Letter, dated as of October 17, 2017, among JPMorgan Chase Bank, Bank of America, N.A., Merrill Lynch, Pierce, Fenner & Smith Incorporated and Amneal Pharmaceuticals LLC (Filed With SEC on May 7, 2018)

Impax Laboratories, Inc. Executive Non-Qualified Deferred Compensation Plan, amended and restated effective January 1, 2008 (Filed With SEC on April 13, 2018)

Business Combination Agreement, dated as of October 17, 2017, among Impax Laboratories, Inc., Amneal Pharmaceuticals LLC, Atlas Holdings, Inc. and K2 Merger Sub Corporation (Filed With SEC on April 13, 2018)

Amendment No. 1, dated as of November 21, 2017, to the Business Combination Agreement, dated as of October 17, 2017, by and among Impax Laboratories, Inc., Atlas Holdings, Inc.,... (Filed With SEC on April 13, 2018)

Letter Agreement, dated as of June 26, 2015, between RBC Capital Markets LLC and Impax regarding the Additional Call Option Transaction (Filed With SEC on April 13, 2018)

Letter Agreement, dated as of June 26, 2015, between RBC Capital Markets LLC and Impax regarding the Additional Warrants (Filed With SEC on April 13, 2018)

Letter Agreement, dated as of June 25, 2015, between RBC Capital Markets LLC and Impax regarding the Base Call Option Transaction (Filed With SEC on April 13, 2018)

Letter Agreement, dated as of June 25, 2015, between RBC Capital Markets LLC and Impax regarding the Base Warrants (Filed With SEC on April 13, 2018)

Amendment to Impax Laboratories, Inc. Executive Non-Qualified Deferred Compensation Plan, effective as of January 1, 2009 (Filed With SEC on April 13, 2018)

Amendment No. 2, dated as of December 16, 2017, to the Business Combination Agreement, dated as of October 17, 2017, by and among Impax Laboratories, Inc., Atlas Holdings, Inc.,... (Filed With SEC on April 13, 2018)

Amendment to Employment Agreement, dated April 1, 2014, by and between Impax Laboratories, Inc. and Bryan M. Reasons (Filed With SEC on April 13, 2018)

Employment Agreement, dated December 12, 2012, by and among Impax Laboratories, Inc. and Bryan M. Reasons (Filed With SEC on April 13, 2018)

Employment Agreement, dated January 24, 2018, by and among Amneal Pharmaceuticals LLC, Amneal Holdings, LLC and Andrew Boyer (Filed With SEC on April 13, 2018)

Employment Agreement, dated March 24, 2017, by and between Impax Laboratories, Inc. and Paul M. Bisaro (Filed With SEC on April 13, 2018)

Memorandum of Understanding, dated December 16, 2017, by and among Amneal Pharmaceuticals LLC, Paul M. Bisaro, Impax Laboratories, Inc., Amneal Holdings, LLC and Atlas Holdings,... (Filed With SEC on April 13, 2018)

Employment Agreement, dated December 16, 2017, by and among Amneal Pharmaceuticals LLC, Atlas Holdings, Inc. and Robert A. Stewart (Filed With SEC on April 13, 2018)

Form of Atlas Holdings, Inc. 2018 Incentive Award Plan (Filed With SEC on April 13, 2018)

Tax Receivable Agreement, among Amneal Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC and the Members of Amneal Pharmaceuticals LLC from time to time party thereto (Filed With SEC on April 13, 2018)

Second Amended and Restated Stockholders Agreement, dated as of December 16, 2017, among Atlas Holdings, Inc., Amneal Pharmaceuticals Holdings Company LLC, AP Class D Member, LLC,... (Filed With SEC on April 13, 2018)

Commitment Letter, dated as of October 17, 2017, among JPMorgan Chase Bank, Bank of America, N.A., Merrill Lynch, Pierce, Fenner & Smith Incorporated and Amneal Pharmaceuticals LLC (Filed With SEC on April 13, 2018)

Supplemental Indenture, dated as of November 6, 2017, between the Company and Wilmington Trust, National Association, as trustee (Filed With SEC on April 13, 2018)

Indenture, dated as of June 30, 2015, between Impax Laboratories, Inc. and Wilmington Trust, National Association, as trustee (Filed With SEC on April 13, 2018)

PIPE Side Letter, dated November 21, 2017, by and among Amneal Holdings, LLC, Atlas Holdings, Inc., and TPG Improv Holdings, L.P (Filed With SEC on April 13, 2018)

Category

Industry

Companies

Contracts

Amneal Pharmaceuticals, Inc. Contracts & Agreements